Skip to main content
. 2013 Jul 22;59(5):479–484. doi: 10.1262/jrd.2013-046

Fig. 3.

Fig. 3.

Advanced increase in plasma luteinizing hormone (LH) levels in female rats treated with a kappa-opioid receptor antagonist, nor-binaltorphimine (nor-BNI), or a neurokinin 3 receptor agonist, senktide. Plasma LH profiles in representative animals are shown in panel A. Arrowheads indicate peaks of LH pulses identified by the PULSAR computer program. Mean LH concentrations and the frequency and amplitude of LH pulses are shown in panel B. The numbers in each column of mean LH concentrations and the frequency of LH pulses indicate the numbers of animals used, and the numbers in each column of the amplitude of LH pulses indicate the number of animals showing LH pulses. Values are means ± SEM. Values with different letters are significantly different (P < 0.05, one-way ANOVA followed by Tukey’s HSD test) from each other. Statistical differences in amplitude of LH pulses were not determined because only one vehicle-treated animal showed an LH pulse.